Introduction
Patients and methods
Study design and data collection
Statistical analysis
Results
Patient, transplant, and disease characteristics
Overall (n = 1711) | de novo (n = 1480) | sAML (n = 231) | P | |
---|---|---|---|---|
Median follow-up (months) [quartiles] | 25.9 [24.5–28.1] | 26.3 [24.5–28.8] | 24.6 [19.6–31.2] | 0.52 |
Patient age (years), median (min–max) [IQR] | 56.4 (18.1–82.5) [44.9–64.4] | 55.8 (18.1–82.5) [44–63.8] | 60.8 (20.8–75.7) [51.6–67.2] | < 0.0001 |
Year transplant, median (min–max) | 2019 (2010–2021) [2017–2020] | 2019 (2010–2021) | 2019 (2010–2021) | 0.58 |
Cytogenetics | ||||
Interm | 1192 (69.7%) | 1037 (70.1%) | 155 (67.1%) | 0.36 |
Adverse | 519 (30.3%) | 443 (29.9%) | 76 (32.9%) | |
Time diagnosis to HSCT (mo), median (min–max) [IQR] | 5.1 (1–23.9) [4–6.7] | 5.2 (1–23.9) [4.1–6.7] | 4.9 (1.3–20.5) [3.5–6.5] | 0.005 |
MRD pre transplant | ||||
neg | 533 (63.2%) | 495 (63.5%) | 38 (59.4%) | 0.51 |
pos | 310 (36.8%) | 284 (36.5%) | 26 (40.6%) | |
Missing | 868 | 701 | 167 | |
HT-CI | ||||
HT-CI = 0 | 798 (55.2%) | 721 (57.1%) | 77 (41.8%) | < 0.0001 |
HT-CI = 1 or 2 | 304 (21%) | 272 (21.6%) | 32 (17.4%) | |
HT-CI ≥ 3 | 344 (23.8%) | 269 (21.3%) | 75 (40.8%) | |
Missing | 265 | 218 | 47 | |
Karnofsky score | ||||
< 90 | 381 (23.3%) | 311 (22%) | 70 (31.5%) | 0.002 |
≥ 90 | 1256 (76.7%) | 1104 (78%) | 152 (68.5%) | |
Missing | 74 | 65 | 9 | |
Patient sex | ||||
Male | 994 (58.1%) | 851 (57.5%) | 143 (61.9%) | 0.21 |
Female | 717 (41.9%) | 629 (42.5%) | 88 (38.1%) | |
Donor sex | ||||
Male | 1052 (61.7%) | 912 (61.8%) | 140 (60.9%) | 0.79 |
Female | 654 (38.3%) | 564 (38.2%) | 90 (39.1%) | |
Missing | 5 | 4 | 1 | |
Female to male combination | ||||
No F → M | 1357 (79.4%) | 1180 (79.8%) | 177 (76.6%) | 0.26 |
F → M | 352 (20.6%) | 298 (20.2%) | 54 (23.4%) | |
Missing | 2 | 2 | 0 | |
Patient CMV | ||||
Neg | 367 (21.7%) | 313 (21.3%) | 54 (23.8%) | 0.4 |
Pos | 1328 (78.3%) | 1155 (78.7%) | 173 (76.2%) | |
Missing | 16 | 12 | 4 | |
Donor CMV | ||||
neg | 643 (38.1%) | 545 (37.3%) | 98 (43.8%) | 0.063 |
pos | 1043 (61.9%) | 917 (62.7%) | 126 (56.2%) | |
Missing | 25 | 18 | 7 | |
Conditioning | ||||
MAC | 823 (48.1%) | 742 (50.1%) | 81 (35.1%) | < 0.0001 |
RIC | 888 (51.9%) | 738 (49.9%) | 150 (64.9%) | |
Cell source | ||||
BM | 483 (28.2%) | 433 (29.3%) | 50 (21.6%) | 0.017 |
PB | 1228 (71.8%) | 1047 (70.7%) | 181 (78.4%) |
Transplantation outcome
Overall (n = 1711) | de novo (n = 1480) | sAML (n = 231) | P | |
---|---|---|---|---|
Engraftment HSCT | ||||
Graft failure | 82 (5%) | 70 (4.9%) | 12 (5.6%) | 0.69 |
Engrafted | 1558 (95%) | 1354 (95.1%) | 204 (94.4%) | |
Mssing | 71 | 56 | 15 | |
cumulative incidence of PMN > 500, day 30 | 91.1% [89.5–92.4] | 86.6% [81.2–90.5] | 0.037 | |
Acute GVHD | ||||
Grade I | 285 (17.4%) | 249 (17.5%) | 36 (16.7%) | Not done |
Grade II | 303 (18.5%) | 255 (18%) | 48 (22.3%) | |
Grade III | 103 (6.3%) | 93 (6.5%) | 10 (4.7%) | |
Grade IV | 38 (2.3%) | 34 (2.4%) | 4 (1.9%) | |
Present, grade unknown | 23 (1.4%) | 21 (1.5%) | 2 (0.9%) | |
No aGvHD present (Grade 0) | 883 (54%) | 768 (54.1%) | 115 (53.5%) | |
Missing | 76 | 60 | 16 |
(A) | |||||
---|---|---|---|---|---|
2 years | |||||
Relapse | NRM | LFS | OS | GRFS | |
de novo | 19.5% [17.2–21.8] | 21.1% [18.9–23.4] | 59.5% [56.6–62.2] | 65.4% [62.5–68] | 49.9% [47–52.7] |
sAML | 21.3% [15.6–27.5] | 20.8% [15.4–26.7] | 58% [50.5–64.7] | 65.7% [58.3–72.1] | 47% [39.5–54.1] |
P value | 0.39 | 0.72 | 0.28 | 0.35 | 0.5 |
180 days | 2 years | |||
---|---|---|---|---|
Acute GVHD II-IV | Acute GVHD III-IV | chronic GVHD | ext. chronic GVHD | |
de novo | 27.2% [24.9–29.6] | 9.2% [7.7–10.8] | 32.2% [29.5–34.9] | 11.9% [10.1–13.9] |
secAML | 29.1% [23.1–35.3] | 6.6% [3.8–10.4] | 33.3% [26.5–40.3] | 11.3% [7.1–16.6] |
P value | 0.55 | 0.23 | 1 | 0.48 |
(B) | |||||
---|---|---|---|---|---|
2 years | |||||
Relapse | NRM | LFS | OS | GRFS | |
de novo | 19.5% [17.2–21.8] | 21.1% [18.9–23.4] | 59.5% [56.6–62.2] | 65.4% [62.5–68] | 49.9% [47–52.7] |
MDS/MPN/BMFS | 21.6% [14.6–29.6] | 17.3% [11.3–24.2] | 61.1% [51.7–69.2] | 70.6% [61.5–77.8] | 46.9% [37.4–55.8] |
OMHD/ST | 20.7% [11.9–31.2] | 27.1% [17.2–38.1] | 52.2% [39.6–63.4] | 57.1% [44.2–68.1] | 46.7% [34.3–58.1] |
P value | 0.68 | 0.58 | 0.3 | 0.22 | 0.79 |
180 days | 2 years | |||
---|---|---|---|---|
Acute GVHD II-IV | Acute GVHD III-IV | Chronic GVHD | Ext. chronic GVHD | |
de novo | 27.2% [24.9–29.6] | 9.2% [7.7–10.8] | 32.2% [29.5–34.9] | 11.9% [10.1–13.9] |
MDS/MPN/BMFS | 30.9% [23.4–38.7] | 6.5% [3.2–11.4] | 38.2% [29.2–47.1] | 13.7% [7.9–21.1] |
OMHD/ST | 25.7% [16.3–36.1] | 6.8% [2.5–14] | 24.4% [14.7–35.4] | 7.4% [2.7–15.3] |
P value | 0.59 | 0.49 | 0.19 | 0.36 |
Multivariate analysis
(A) | ||||||
---|---|---|---|---|---|---|
RELAPSE | NRM | LFS | ||||
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
sAML versus do novo | 1.02 (0.72–1.45) | 0.91 | 0.97 (0.7–1.35) | 0.87 | 1 (0.79–1.27) | 0.99 |
Patient age (per 10 years) | 0.98 (0.89–1.08) | 0.62 | 1.36 (1.21–1.52) | < 0.0001 | 1.14 (1.06–1.23) | 5.00E−04 |
Adverse versus intermediate cytogenetics | 1.95 (1.53–2.49) | < 0.0001 | 1.22 (0.95–1.56) | 0.12 | 1.54 (1.29–1.83) | < 0.0001 |
Time diagnosis to HSCT (mo) | 1 (0.96–1.04) | 0.86 | 1.03 (0.99–1.06) | 0.13 | 1.01 (0.99–1.04) | 0.36 |
KPS > 90 | 0.79 (0.59–1.04) | 0.09 | 0.7 (0.54–0.92) | 0.009 | 0.73 (0.6–0.88) | 0.001 |
RIC versus MAC | 1.4 (1.06–1.85) | 0.016 | 1.1 (0.84–1.45) | 0.48 | 1.24 (1.02–1.5) | 0.031 |
Female to male versus other | 1.22 (0.91–1.63) | 0.18 | 1.25 (0.95–1.65) | 0.1 | 1.24 (1.02–1.52) | 0.031 |
Pat. CMV pos | 1.04 (0.77–1.42) | 0.78 | 1.33 (0.95–1.85) | 0.094 | 1.17 (0.93–1.46) | 0.18 |
Don. CMV pos | 0.85 (0.65–1.1) | 0.21 | 1.14 (0.88–1.48) | 0.32 | 0.99 (0.82–1.19) | 0.93 |
PBSC versus BM | 0.91 (0.7–1.19) | 0.49 | 0.93 (0.7–1.22) | 0.58 | 0.92 (0.76–1.11) | 0.39 |
Centre (frailty term) | 0.24 | 0.014 | 0.11 |
OS | GRFS | Acute GVHD II-IV | ||||
---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
sAML versus do novo | 0.95 (0.74–1.23) | 0.72 | 0.94 (0.75–1.17) | 0.57 | 1.04 (0.77–1.41) | 0.8 |
Patient age (per 10 years) | 1.22 (1.13–1.33) | < 0.0001 | 1.09 (1.02–1.17) | 0.008 | 1.07 (0.97–1.17) | 0.16 |
Adverse versus intermediate cytogenetics | 1.56 (1.29–1.87) | < 0.0001 | 1.44 (1.24–1.69) | < 0.0001 | 0.99 (0.8–1.24) | 0.94 |
Time diagnosis to HSCT (mo) | 1.01 (0.99–1.04) | 0.34 | 1 (0.98–1.03) | 0.71 | 0.97 (0.94–1.01) | 0.098 |
KPS > 90 | 0.74 (0.6–0.91) | 0.005 | 0.81 (0.68–0.97) | 0.019 | 0.82 (0.64–1.06) | 0.13 |
RIC versus MAC | 1.29 (1.05–1.59) | 0.018 | 1.18 (0.99–1.41) | 0.072 | 0.95 (0.74–1.22) | 0.68 |
Female to male versus other | 1.3 (1.05–1.6) | 0.015 | 1.28 (1.07–1.53) | 0.006 | 0.81 (0.62–1.05) | 0.12 |
Pat. CMV pos | 1.16 (0.91–1.48) | 0.23 | 1.1 (0.9–1.34) | 0.35 | 1.01 (0.77–1.31) | 0.97 |
Don. CMV pos | 1.05 (0.86–1.28) | 0.65 | 0.99 (0.84–1.18) | 0.95 | 1.02 (0.81–1.27) | 0.89 |
PBCS versus BM | 0.89 (0.72–1.09) | 0.26 | 1.12 (0.93–1.34) | 0.23 | 1.79 (1.35–2.39) | < 0.0001 |
Centre (frailty term) | 0.017 | 0.015 | < 0.0001 |
Acute GVHD III–IV | Chronic GVHD | Extensive chronic GVHD | ||||
---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
sAML versus do novo | 0.73 (0.41–1.32) | 0.3 | 0.96 (0.71–1.29) | 0.78 | 0.65 (0.39–1.08) | 0.097 |
Patient age (per 10 years) | 1.01 (0.87–1.17) | 0.92 | 1.07 (0.99–1.17) | 0.1 | 1.09 (0.95–1.25) | 0.24 |
Adverse versus intermediate cytogenetics | 1.03 (0.7–1.51) | 0.89 | 1.06 (0.85–1.32) | 0.63 | 1.32 (0.93–1.86) | 0.11 |
Time diagnosis to HSCT (mo) | 0.98 (0.92–1.04) | 0.5 | 1.01 (0.97–1.04) | 0.76 | 1 (0.94–1.05) | 0.88 |
KPS > 90 | 0.8 (0.52–1.21) | 0.29 | 1.06 (0.82–1.37) | 0.68 | 1.05 (0.7–1.58) | 0.82 |
RIC versus MAC | 0.93 (0.61–1.39) | 0.71 | 1.14 (0.9–1.45) | 0.27 | 1.11 (0.76–1.64) | 0.58 |
Female to male versus other | 0.89 (0.56–1.41) | 0.63 | 1.17 (0.92–1.49) | 0.2 | 1.52 (1.05–2.19) | 0.027 |
Pat. CMV pos | 0.9 (0.58–1.41) | 0.66 | 0.97 (0.74–1.26) | 0.81 | 0.99 (0.64–1.54) | 0.97 |
Don. CMV pos | 1.01 (0.68–1.49) | 0.98 | 1.02 (0.81–1.27) | 0.89 | 1.21 (0.83–1.76) | 0.31 |
PBCS versus BM | 1.73 (1.09–2.74) | 0.019 | 1.55 (1.19–2.02) | 0.001 | 1.52 (0.99–2.34) | 0.056 |
Centre (frailty term) | 0.24 | 0.0005 | 0.0001 |
(B) | ||||||
---|---|---|---|---|---|---|
RELAPSE | NRM | LFS | ||||
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
de novo AML (reference) | 1 | 1 | 1 | |||
MDS/MPN/BMFS | 1.02 (0.67–1.56) | 0.91 | 0.87 (0.57–1.31) | 0.5 | 0.95 (0.71–1.27) | 0.73 |
OMHD/ST | 1.01 (0.58–1.76) | 0.96 | 1.18 (0.72–1.93) | 0.52 | 1.1 (0.76–1.59) | 0.62 |
Patient age (per 10 years) | 0.98 (0.89–1.08) | 0.62 | 1.36 (1.21–1.52) | < 0.0001 | 1.14 (1.06–1.23) | 0.0005 |
Adverse versus intermediate cytogenetics | 1.95 (1.53–2.49) | < 0.0001 | 1.21 (0.94–1.56) | 0.13 | 1.53 (1.29–1.82) | < 0.0001 |
Time diagnosis to HSCT (mo) | 1 (0.96–1.04) | 0.86 | 1.03 (0.99–1.06) | 0.14 | 1.01 (0.99–1.04) | 0.38 |
KPS > 90 | 0.79 (0.59–1.04) | 0.09 | 0.7 (0.54–0.92) | 0.009 | 0.73 (0.6–0.89) | 0.001 |
RIC versus MAC | 1.4 (1.06–1.85) | 0.016 | 1.1 (0.84–1.45) | 0.48 | 1.24 (1.02–1.5) | 0.031 |
Female to male versus other | 1.22 (0.91–1.63) | 0.18 | 1.27 (0.96–1.67) | 0.091 | 1.25 (1.02–1.52) | 0.029 |
Pat. CMV pos | 1.04 (0.77–1.42) | 0.78 | 1.32 (0.95–1.85) | 0.098 | 1.17 (0.93–1.46) | 0.18 |
Don. CMV pos | 0.85 (0.65–1.1) | 0.21 | 1.14 (0.88–1.48) | 0.32 | 0.99 (0.82–1.19) | 0.93 |
PBSC versus BM | 0.91 (0.7–1.19) | 0.49 | 0.92 (0.7–1.22) | 0.57 | 0.92 (0.76–1.11) | 0.38 |
Centre (frailty term) | 0.24 | 0.012 | 0.1 |
OS | GRFS | Acute GVHD II–IV | ||||
---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
de novo AML (reference) | 1 | 1 | 1 | |||
MDS/MPN/BMFS | 0.88 (0.64–1.21) | 0.43 | 0.97 (0.75–1.25) | 0.8 | 1.09 (0.76–1.55) | 0.65 |
OMHD/ST | 1.1 (0.74–1.63) | 0.63 | 0.89 (0.62–1.27) | 0.52 | 0.95 (0.57–1.58) | 0.84 |
Patient age (per 10 years) | 1.22 (1.13–1.33) | < 0.0001 | 1.09 (1.02–1.17) | 0.009 | 1.07 (0.97–1.17) | 0.16 |
Adverse versus intermediate cytogenetics | 1.55 (1.29–1.87) | < 0.0001 | 1.45 (1.24–1.69) | < 0.0001 | 0.99 (0.8–1.24) | 0.96 |
Time diagnosis to HSCT (mo) | 1.01 (0.98–1.04) | 0.36 | 1 (0.98–1.03) | 0.69 | 0.97 (0.94–1.01) | 0.1 |
KPS > 90 | 0.74 (0.6–0.91) | 0.005 | 0.81 (0.67–0.96) | 0.019 | 0.82 (0.64–1.05) | 0.12 |
RIC versus MAC | 1.29 (1.04–1.59) | 0.018 | 1.18 (0.99–1.41) | 0.071 | 0.95 (0.74–1.22) | 0.68 |
Female to male versus other | 1.3 (1.06–1.61) | 0.014 | 1.28 (1.07–1.53) | 0.007 | 0.81 (0.62–1.05) | 0.11 |
Pat. CMV pos | 1.16 (0.91–1.47) | 0.24 | 1.1 (0.9–1.34) | 0.35 | 1.01 (0.77–1.31) | 0.97 |
Don. CMV pos | 1.05 (0.86–1.28) | 0.66 | 0.99 (0.84–1.18) | 0.95 | 1.02 (0.81–1.27) | 0.9 |
PBCS versus BM | 0.89 (0.72–1.09) | 0.25 | 1.12 (0.93–1.34) | 0.23 | 1.79 (1.35–2.39) | < 0.0001 |
Centre (frailty term) | 0.015 | 0.016 | < 0.0001 |
Acute GVHD III-IV | Chronic GVHD | Extensive chronic GVHD | ||||
---|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
de novo AML (reference) | 1 | 1 | 1 | |||
MDS/MPN/BMFS | 0.77 (0.39–1.55) | 0.47 | 1.14 (0.82–1.6) | 0.42 | 0.81 (0.46–1.42) | 0.46 |
OMHD/ST | 0.66 (0.24–1.81) | 0.42 | 0.62 (0.35–1.09) | 0.099 | 0.32 (0.1–1.02) | 0.055 |
Patient age (per 10 years) | 1.01 (0.87–1.17) | 0.92 | 1.07 (0.99–1.17) | 0.099 | 1.08 (0.94–1.24) | 0.25 |
Adverse versus intermediate cytogenetics | 1.03 (0.7–1.51) | 0.88 | 1.07 (0.86–1.33) | 0.56 | 1.34 (0.95–1.89) | 0.098 |
Time diagnosis to HSCT (mo) | 0.98 (0.92–1.04) | 0.51 | 1.01 (0.98–1.04) | 0.66 | 1 (0.95–1.05) | 0.97 |
KPS > 90 | 0.8 (0.52–1.21) | 0.29 | 1.05 (0.81–1.36) | 0.7 | 1.03 (0.69–1.55) | 0.88 |
RIC versus MAC | 0.93 (0.61–1.4) | 0.71 | 1.14 (0.9–1.45) | 0.27 | 1.12 (0.76–1.65) | 0.55 |
Female to male versus other | 0.89 (0.56–1.41) | 0.62 | 1.17 (0.92–1.49) | 0.21 | 1.52 (1.05–2.2) | 0.027 |
Pat. CMV pos | 0.91 (0.58–1.41) | 0.66 | 0.97 (0.75–1.27) | 0.83 | 0.99 (0.64–1.54) | 0.98 |
Don. CMV pos | 1.01 (0.68–1.49) | 0.98 | 1.02 (0.81–1.27) | 0.88 | 1.22 (0.84–1.77) | 0.3 |
PBCS versus BM | 1.73 (1.09–2.74) | 0.019 | 1.55 (1.19–2.02) | 0.001 | 1.52 (0.99–2.34) | 0.055 |
Centre (fraitly term) | 0.24 | 0.0006 | 0.0002 |
Cause of death
Overall (n = 564) | de novo (n = 485) | sAML (n = 79) | |
---|---|---|---|
Original disease | 201 (37.2%) | 169 (36.3%) | 32 (42.1%) |
Infection | 162 (29.9%) | 142 (30.5%) | 20 (26.3%) |
GVHD | 75 (13.9%) | 68 (14.6%) | 7 (9.2%) |
Non HSCT related | 34 (6.3%) | 26 (5.6%) | 8 (10.5%) |
Other transp related | 17 (3.1%) | 17 (3.7%) | 0 (0%) |
MOF | 14 (2.6%) | 11 (2.4%) | 3 (3.9%) |
VOD | 10 (1.8%) | 10 (2.2%) | 0 (0%) |
Cardiac toxicity | 7 (1.3%) | 6 (1.3%) | 1 (1.3%) |
Other second malignancy | 6 (1.1%) | 5 (1.1%) | 1 (1.3%) |
Haemorhage | 6 (1.1%) | 4 (0.9%) | 2 (2.6%) |
Failure/Rejection | 4 (0.7%) | 3 (0.6%) | 1 (1.3%) |
CNS toxicity | 4 (0.7%) | 3 (0.6%) | 1 (1.3%) |
IP | 1 (0.2%) | 1 (0.2%) | 0 (0%) |
Missing | 23 | 20 | 3 |
Matched-pair analysis
(A) | |||||
---|---|---|---|---|---|
2 years | |||||
Relapse | NRM | LFS | OS | GRFS | |
de novo | 21.4% [17–26.1] | 23.4% [19–28.1] | 55.2% [49.5–60.5] | 61.4% [55.7–66.5] | 46.3% [40.7–51.6] |
sAML | 21% [15.1–27.5] | 20.6% [15.1–26.8] | 58.4% [50.6–65.4] | 66.4% [58.8–73] | 48.2% [40.4–55.6] |
sAML versus de novo AML | 0.98 (0.67–1.42) | 0.92 (0.64–1.33) | 0.95 (0.74–1.22) | 0.91 (0.69–1.2) | 0.92 (0.73–1.16) |
p value (cluster = pair) | 0.9 | 0.67 | 0.67 | 0.51 | 0.48 |
180 days | 2 years | |||
---|---|---|---|---|
Acute GVHD II-IV | Acute GVHD III-IV | chronic GVHD | ext. chronic GVHD | |
de novo | 27.6% [23.2–32.1] | 9.5% [6.9–12.7] | 31.8% [26.7–37] | 10.2% [7.2–13.8] |
sAML | 27.7% [21.6–34.1] | 6.7% [3.7–10.8] | 32.8% [25.7–40.1] | 10.6% [6.4–16.1] |
sAML versus de novo AML | 0.99 (0.72–1.38) | 0.7 (0.36–1.35) | 1.03 (0.75–1.42) | 0.93 (0.53–1.61) |
p value (cluster = pair) | 0.96 | 0.29 | 0.84 | 0.79 |
(B) | |||||
---|---|---|---|---|---|
2 years | |||||
Relapse | NRM | LFS | OS | GRFS | |
de novo AML | 21.4% [17–26.1] | 23.4% [19–28.1] | 55.2% [49.5–60.5] | 61.4% [55.7–66.5] | 46.3% [40.7–51.6] |
MDS/MPN/BMFS | 21.5% [14.3–29.7] | 17.2% [11–24.5] | 61.3% [51.5–69.7] | 70.7% [61.4–78.2] | 47% [37.2–56.2] |
OMHD/ST | 19.9% [10.8–30.9] | 27.1% [16.6–38.7] | 53% [39.6–64.8] | 58.6% [44.8–70.1] | 50.1% [36.8–62] |
MDS/MPN/BMFS versus de novo | |||||
HR (95% CI) | 0.98 (0.63–1.52) | 0.84 (0.53–1.31) | 0.9 (0.67–1.22) | 0.84 (0.6–1.18) | 0.96 (0.74–1.25) |
p value | 0.92 | 0.44 | 0.5 | 0.33 | 0.76 |
OMHD/ST | |||||
HR (95% CI) | 0.98 (0.55–1.75) | 1.09 (0.64–1.84) | 1.04 (0.7–1.53) | 1.04 (0.69–1.58) | 0.85 (0.58–1.24) |
p value | 0.94 | 0.75 | 0.85 | 0.85 | 0.4 |
180 days | 2 years | |||
---|---|---|---|---|
Acute GVHD II–IV | Acute GVHD III–IV | Chronic GVHD | ext. chronic GVHD | |
de novo AML | 27.6% [23.2–32.1] | 9.5% [6.9–12.7] | 31.8% [26.7–37] | 10.2% [7.2–13.8] |
MDS/MPN/BMFS | 29.1% [21.5–37.2] | 7.1% [3.5–12.4] | 38.3% [29–47.5] | 13.8% [7.8–21.4] |
OMHD/ST | 25% [15.4–35.8] | 5.9% [1.9–13.3] | 22.3% [12.5–33.9] | 5% [1.3–12.8] |
MDS/MPN/BMFS versus de novo | ||||
HR (95% CI) | 1.05 (0.73–1.51) | 0.75 (0.35–1.57) | 1.24 (0.88–1.74) | 1.22 (0.68–2.17) |
p value | 0.78 | 0.44 | 0.22 | 0.5 |
OMHD/ST | ||||
HR (95% CI) | 0.88 (0.52–1.49) | 0.62 (0.21–1.78) | 0.67 (0.38–1.19) | 0.42 (0.13–1.39) |
p value | 0.64 | 0.37 | 0.17 | 0.15 |